Finding ways to increase the secretion of a kidney protein linked to disease
Official title: Assay development and optimization for a high throughput screen to detect compounds increasing secretion of C150S mutant Uromodulin
Funded at University of Michigan at Ann Arbor · NIH-11091908 · Data updated 2026-11-12
This study is looking at a genetic change that causes a kidney disease called ADTKD-UMOD, and researchers are testing different substances to see if they can help the body get rid of the faulty protein, which could lead to new treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $314,702 |
| NIH project number | 7R01DK119631-05 |
| Project ID | NIH-11091908 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with autosomal-dominant tubulo-interstitial kidney disease due to Uromodulin mutations.
✕Less likely to help
Patients without Uromodulin mutations or those with other forms of kidney disease may not benefit from this research.
What this research studies
This research focuses on a genetic mutation in the Uromodulin protein that leads to a kidney disease called ADTKD-UMOD, which currently has no specific treatment. The researchers have developed a cell culture assay to study how this mutated protein behaves and are screening various compounds to find those that can enhance the secretion of the mutant protein. By increasing the secretion of this protein, the goal is to reduce cell death and slow the progression of kidney disease. Patients may benefit from new therapeutic options that arise from identifying effective compounds.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve kidney function and quality of life for patients with ADTKD-UMOD.
How similar studies have gone: Other research has shown promise in enhancing protein secretion in similar contexts, suggesting that this approach may be viable.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Wolf, Matthias Tilmann Florian — University of Michigan at Ann Arbor
- Study coordinator: Wolf, Matthias Tilmann Florian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.